FMP
GoodRx Holdings, Inc.
GDRX
NASDAQ
GoodRx Holdings, Inc., through its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices through GoodRx codes that are used to save money on prescriptions across the United States. It also offers other healthcare products and services, including subscriptions, pharma manufacturer solutions, and telehealth services. It serves pharmacy benefit managers that manage formularies and prescription transactions, including establishing pricing between consumers and pharmacies. The company was incorporated in 2015 and is headquartered in Santa Monica, California.
4.64 USD
0.01 (0.216%)
Historical Prices
From:
To:
About
ceo
Ms. Wendy Barnes
sector
Healthcare
industry
Medical - Healthcare Information Services
website
https://www.goodrx.comexchange
NASDAQ
Description
GoodRx Holdings, Inc., through its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices through GoodRx codes that are used to save money on prescriptions across the United States. It also offers other healthcare products and services, including subscriptions, pharma manufacturer solutions, and telehealth services. It serves pharmacy benefit managers that manage formularies and prescription transactions, including establishing pricing...
CIK
0001809519
ISIN
US38246G1085
CUSIP
38246G108
Address
2701 Olympic Boulevard
Phone
855 268 2822
Country
US
Employee
738
IPO Date
Sep 23, 2020
Financial Statement
Earnings
GDRX Financial Summary
CIK
0001809519
Exchange
NASDAQ
Industry
Medical - Healthcare...
Sector
Healthcare
CUSIP
38246G108
ISIN
US38246G1085
Country
US
Price
4.64
Beta
1.26
Volume Avg.
1.41M
Market Cap
1.78B
Shares
-
52-Week
3.82-9.26
DCF
4.7
ROE
-
ROA
-
Operating Margin
-
Debt/Equity
-
P/E
116
P/B
-
Website
https://www.goodrx.com
Upgrades and Downgrades
We are unable to load the data!
Financial Information
Financial Summary Real-Time Price
Financial Statements
Financial Quarter Statements
Ratios Analysis
Dupont Analysis
Free Cashflow
Operating Data
Balance Sheet Data
Financial Modelling
Discounted Cashflow Model
Discounted Cashflow Model Levered
Free Cashflow Build-Up
Terminal Value
Intrinsic Value
Weighted Average Cost of Capital
Market Information
Stock Value
Latest GDRX News
Danny Green
Mar 27, 2025
GoodRx Holdings, Inc. (NASDAQ:GDRX) Financial Efficiency Ana...
GoodRx Holdings, Inc. (NASDAQ:GDRX) is a digital healthcare platform that provides consumers with access to affordable prescription medications. The company operates in a competitive landscape alongside peers like American Well Corporation, JFrog Ltd., Asana, Inc., nCino, Inc., and Doximity, Inc. These companies are part of the broader healthcare and technology sectors, each with unique business models and financial metrics. In evaluating GoodRx's financial efficiency, its Return on Invested Ca...
Andrew Wynn
Mar 8, 2025
GoodRx Holdings, Inc. (NASDAQ:GDRX) Financial Performance An...
GoodRx Holdings, Inc. (NASDAQ:GDRX) is a digital healthcare platform that provides consumers with information and tools to compare prescription drug prices and access discounts. The company operates in a competitive landscape alongside other digital health and software companies. A key metric to assess its financial performance is the comparison between Return on Invested Capital (ROIC) and Weighted Average Cost of Capital (WACC). GoodRx's ROIC is 3.25%, while its WACC is 11.62%, resulting in a...
Gordon Thompson
Dec 5, 2024
GoodRx Holdings, Inc. (NASDAQ:GDRX) Outperforms in Capital E...
GoodRx Holdings, Inc. (NASDAQ:GDRX) is a company that provides a platform to help consumers find affordable prescription medications. It operates in the healthcare sector, offering price comparisons and discounts on prescription drugs. GoodRx competes with other companies in the digital health and telemedicine space, such as American Well Corporation (AMWL) and Doximity, Inc. (DOCS). In evaluating GoodRx's financial performance, the Return on Invested Capital (ROIC) and Weighted Average Cost of...
Alex Lavoie
Nov 19, 2024
GoodRx Holdings, Inc. (NASDAQ:GDRX) Financial Performance an...
GoodRx Holdings, Inc. (NASDAQ:GDRX) is a company that provides a platform to compare prescription drug prices and offers discounts on medications. It operates in the healthcare sector, focusing on making medications more affordable for consumers. GoodRx competes with other companies in the digital health and telemedicine space, such as American Well Corporation and Doximity, Inc. In evaluating GoodRx's financial performance, the Return on Invested Capital (ROIC) is 10.56%, while the Weighted Av...
Zacks Investment Research
Aug 8, 2024
GoodRx (GDRX) Reports Q2 Earnings: What Key Metrics Have to ...
Although the revenue and EPS for GoodRx (GDRX) give a sense of how its business performed in the quarter ended June 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Zacks Investment Research
Aug 8, 2024
GoodRx Holdings, Inc. (GDRX) Misses Q2 Earnings and Revenue ...
GoodRx Holdings, Inc. (GDRX) came out with quarterly earnings of $0.08 per share, missing the Zacks Consensus Estimate of $0.09 per share. This compares to earnings of $0.07 per share a year ago.
Zacks Investment Research
Aug 6, 2024
Unveiling GoodRx (GDRX) Q2 Outlook: Wall Street Estimates fo...
Besides Wall Street's top -and-bottom-line estimates for GoodRx (GDRX), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended June 2024.
Seeking Alpha
Jul 31, 2024
GoodRx Q2 Earnings Preview
GoodRx stock rated a sell due to industry headwinds, cost growth outpacing revenue, and needing 12%+ growth to justify price. Q2 earnings expected to be in line with guidance, but long-term guidance doesn't support current price point. Upside potential if GoodRx doubles market growth, but industry headwinds and growth struggles pose challenges.
